1. Most Discussed
  2. Gainers & Losers
KZA 45.0¢

any ideas?

  1. munch

    3,567 Posts.

    Are the following two derivatives for breast and lung? I assume NV50 is now named NV5063 (or has been replaced by it), and assume the other is for lung cancer as stated by the annual report. Given we should see NV5063 start an oral trial in the UK sometime soon, does anyone know when the lung cancer trial will start... perhaps it's still pre-clinical.

    "Phenoxodiol derivatives:

    We have constructed a number of analogues (or derivatives) of phenoxodiol in order to explore the opportunity of creating drugs with more potent activity against specific cancer types. Two such drugs (NV50 and NV47) have emerged as being more potent than phenoxodiol against selected tumour types and these currently are undergoing pre-clinical studies ahead of clinical trials next year. "

Before making any financial decisions based on what you read, always consult an advisor or expert.

The HotCopper website is operated by Report Card Pty Ltd. Any information posted on the website has been prepared without taking into account your objectives, financial situation or needs and as such, you should before acting on the information or advice, consider the appropriateness of the information or advice in relation to your objectives, financial situation or needs. Please be aware that any information posted on this site should not be considered to be financial product advice.

From time to time comments aimed at manipulating other investors may appear on these forums. Posters may post overly optimistic or pessimistic comments on particular stocks, in an attempt to influence other investors. It is not possible for management to moderate all posts so some misleading and inaccurate posts may still appear on these forums. If you do have serious concerns with a post or posts you should report a Terms of Use Violation (TOU) on the link above. Unless specifically stated persons posting on this site are NOT investment advisors and do NOT hold the necessary licence, or have any formal training, to give investment advice.


Thank you for visiting HotCopper

We have detected that you are running ad blocking software.

HotCopper relies on revenue generated from advertisers. Kindly disable your ad blocking software to return to the HotCopper website.

I understand, I have disabled my ad blocker. Let me in!

Need help? Click here for support.